Denali Therapeutics Inc.
DNLI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.78 | 0.63 | -0.27 | -1.19 |
| FCF Yield | -4.23% | -3.32% | -5.86% | -2.56% |
| EV / EBITDA | -17.88 | -19.03 | -16.30 | -26.25 |
| Quality | ||||
| ROIC | -14.10% | -12.45% | -12.25% | -10.12% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.61 | 0.99 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -33.10% | 41.72% | -53.76% | -40.91% |
| Safety | ||||
| Net Debt / EBITDA | 0.34 | 0.78 | 0.06 | 0.99 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -320.51 | 0.00 | 0.00 |